

# Human Adenocarcinoma Cell Line Of Non-Small-Cell Lung Cancer, #NCI-H1993

---

SKU: CDS10539 | Category: Cell Lines — Cancer Cell Lines

**Validation & Biomarker Data Guide** · Lineage classification: Lung carcinoma cell line

## 1. Product Overview

Human Adenocarcinoma Cell Line Of Non-Small-Cell Lung Cancer, #NCI-H1993 is an established tumor-derived cell line for in vitro oncology research. It is suitable for studies of tumor cell biology, proliferation and viability, signaling, biomarkers, drug response, cytotoxicity and cell-based assay development. The model can be incorporated into screening and mechanistic workflows under validated culture conditions. For research use only.

Primary tissue / source: Adenocarcinoma Of Non-Small- Lung Cancer | Growth type: Adherent Cells | Tumorigenic status: Tumor Cells | Pack size: 1 x 1 million cells

## 2. Typical Applications

- 1. Cancer Biology Research
  - Mechanistic Studies
  - Gene Function Studies
  - Signal Transduction
- 2. Drug Discovery and Development
  - Screening of Anticancer Compounds
  - IC50/EC50 Studies
  - Mechanism of Action
  - Combination Therapies
- 3. Assay Development
  - ELISA and Immunoassays
  - Flow Cytometry Assays

## 3. Identity & Phenotypic Marker Panel

A representative identity panel for lung carcinoma cell line products is shown below. Actual per-lot Certificates of Analysis should be consulted for verified identity data.

| Marker          | Expected Result | Range             |
|-----------------|-----------------|-------------------|
| TTF-1           | Positive        | 40–80% positive   |
| Pan-cytokeratin | Positive        | 80–98% positive   |
| CK7             | Positive        | 45–85% positive   |
| Vimentin        | Negative / low  | ≤30% (background) |




Figure 1. Marker expression profile (mean ± SD, n = 3 replicates).

#### 4. Growth Kinetics & Viability

Growth and viability trends over 120 hours in standard culture conditions.




Figure 2. Growth curve (viable cell density, left axis) and viability trend (right axis).

## 5. Functional Validation Assay

**Proliferation / drug-sensitivity assay:** MTT/CellTiter-Glo viability assay across a reference cytotoxic compound (e.g. cisplatin) dose range to generate an IC<sub>50</sub> curve confirming assay-ready drug responsiveness.




Figure 3. Functional assay readout — IC<sub>50</sub> ≈ 6.9 μM.

## 6. QC Acceptance Criteria

| Acceptance Criterion                                        | Result                    |
|-------------------------------------------------------------|---------------------------|
| Authenticated by STR profiling                              | PASS                      |
| ≥70% pan-cytokeratin+ by ICC                                | PASS                      |
| IC <sub>50</sub> within historical reference range for line | PASS                      |
| Apparent population doubling time                           | ≈ 33 hours                |
| Functional assay outcome                                    | IC <sub>50</sub> ≈ 6.9 μM |

## 7. Handling & Culture Notes

- Refer to the product-specific Certificate of Analysis and datasheet for validated culture medium, seeding density, and passaging recommendations.
- As with any primary cell or cell line, confirm mycoplasma-negative status, expected morphology by phase-contrast microscopy, and viability by trypan blue or equivalent dye-exclusion assay at each passage before use in downstream assays.